Presidential Symposium
Invited discussant
Date
20 Dec 2015Session
Presidential SymposiumPresenters
Tony S.K. MokAuthors
T.S.K. MokAuthor affiliations
- Department Of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong/CN
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
656 - Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
Presenter: Keunchil Park
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
1374 - KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy
Presenter: Roy S. Herbst
Session: Presidential Symposium
Resources:
Abstract
Slides
Webcast
856 - Prioritizing strategies to address the economic impact of cancer in Southeast Asia
Presenter: Nirmala Bhoo-Pathy
Session: Presidential Symposium
Resources:
Abstract
Invited discussant
Presenter: Roman Rouzier
Session: Presidential Symposium
Resources:
Slides
Webcast
Invited discussant
Presenter: Pasi Jänne
Session: Presidential Symposium
Resources:
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.